GC 3110A

Drug Profile

GC 3110A

Alternative Names: GC-3110A; GC-3110B; GCFlu Quadrivalent; Quadrivalent influenza virus vaccine - Green Cross Corporation; Seasonal influenza virus vaccine quadrivalent - Green Cross

Latest Information Update: 06 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Green Cross
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Influenza virus infections

Most Recent Events

  • 19 Sep 2017 Green Cross plans a phase III trial for Influenza virus infections (Prevention, In Infants, In children) in South Korea (IM,Injection) in September 2017 (NCT03285997)
  • 08 May 2017 Green Cross completes a phase III trial for Influenza virus infections (In the elderly, Prevention) in South Korea (IM) (NCT02917304)
  • 01 Oct 2016 Phase-III clinical trials in Influenza virus infections (Prevention, In the elderly) in South Korea (IM) (NCT02917304)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top